Serotonin4 (5-HT4) receptor Agonists are putative antidepressants with a rapid onset of action

被引:270
作者
Lucas, Guillaume
Rymar, Vladimir V.
Du, Jenny
Mnie-Filali, Ouissame
Bisgaard, Christina
Manta, Stella
Lambas-Senas, Laura
Wiborg, Ove
Haddjeri, Nasser
Pineyro, Graciela
Sadikot, Abbas F.
Debonnel, Guy
机构
[1] McGill Univ, Dept Psychiat, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurochirurg, Montreal, PQ H3A 2B4, Canada
[3] Univ Montreal, Ctr Rech Fernard Seguin, Montreal, PQ H1N 3V2, Canada
[4] Univ Lyon 1, Lab Neuropharmacol & Neurochim, Lyon, France
[5] Aarhus Psychiat Univ Hosp, Ctr Basic Psychiat Res, Aarhus, Denmark
[6] OWn Res Aps, Aarhus, Denmark
关键词
D O I
10.1016/j.neuron.2007.07.041
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Current antidepressants are clinically effective only after several weeks of administration. Here, we show that serotonin(4) (5-HT4) agonists reduce immobility in the forced swimming test, displaying an antidepressant potential. Moreover, a 3 day regimen with such compounds modifies rat brain parameters considered to be key markers of antidepressant action, but that are observed only after 2-3 week treatments with classical molecules: desensitization of 5-HT1A autoreceptors, increased tonus on hippocampal postsynaptic 5-HT1A receptors, and enhanced phosphorylation of the CREB protein and neurogenesis in the hippocampus. In contrast, a 3 day treatment with the SSRI citalopram remains devoid of any effect on these parameters. Finally, a 3 day regimen with the 5-HT4 agonist RS 67333 was sufficient to reduce both the hyperlocomotion induced by olfactory bulbectomy and the diminution of sucrose intake consecutive to a chronic mild stress. These findings point out 5-HT4 receptor agonists as a putative class of antidepressants with a rapid onset of action.
引用
收藏
页码:712 / 725
页数:14
相关论文
共 51 条
[1]   Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation [J].
Arborelius, L ;
Hawks, BW ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
PSYCHOPHARMACOLOGY, 2004, 176 (3-4) :248-U5
[2]  
Artigas Francesc, 2002, Psychopharmacol Bull, V36 Suppl 2, P123
[3]   Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain [J].
Besson, A ;
Haddjeri, N ;
Blier, P ;
de Montigny, C .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2000, 10 (03) :177-188
[4]  
Blier P, 2001, J CLIN PSYCHIAT, V62, P7
[5]   CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION [J].
BLIER, P ;
DEMONTIGNY, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) :220-226
[6]   Is there a role for 5-HT1A agonists in the treatment of depression? [J].
Blier, P ;
Ward, NM .
BIOLOGICAL PSYCHIATRY, 2003, 53 (03) :193-203
[7]  
BLIER P, 1999, NUROPSYCHOPHARMACO S, V21
[8]   A COMPARISON OF THE EFFECTS OF DIAZEPAM VERSUS SEVERAL TYPICAL AND ATYPICAL ANTI-DEPRESSANT DRUGS IN AN ANIMAL-MODEL OF ANXIETY [J].
BODNOFF, SR ;
SURANYICADOTTE, B ;
QUIRION, R ;
MEANEY, MJ .
PSYCHOPHARMACOLOGY, 1989, 97 (02) :277-279
[9]   The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound [J].
Briejer, MR ;
Bosmans, JP ;
Van Daele, P ;
Jurzak, M ;
Heylen, L ;
Leysen, JE ;
Prins, NH ;
Schuurkes, JAJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 423 (01) :71-83
[10]   Neurotrophic effects of antidepressant drugs [J].
Castrén, E .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (01) :58-64